Global Oncology Based Preclinical CRO Market Growth (Status and Outlook) 2023-2029

Global Oncology Based Preclinical CRO Market Growth (Status and Outlook) 2023-2029

Preclinical research refers to before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. A Preclinical CRO, or preclinical contract research organization, provides the experience, knowledge, and skill required to take a pharmaceutical product or medical device from the drawing board to distribution. This journey entails a plethora of activities that involve scientists, medical personnel, administrators, governmental and industry liaisons, marketing experts, and a host of other technical and creative individuals. Rarely is this unique combination of credentials and craft already present within a sponsoring organization. The CRO industry emerged to fill this much-needed role, to provide the expertise required to bring a pharmaceutical product or medical device into the marketplace as quickly and smoothly as possible.
LPI (LP Information)' newest research report, the “Oncology Based Preclinical CRO Industry Forecast” looks at past sales and reviews total world Oncology Based Preclinical CRO sales in 2022, providing a comprehensive analysis by region and market sector of projected Oncology Based Preclinical CRO sales for 2023 through 2029. With Oncology Based Preclinical CRO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oncology Based Preclinical CRO industry.
This Insight Report provides a comprehensive analysis of the global Oncology Based Preclinical CRO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oncology Based Preclinical CRO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oncology Based Preclinical CRO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oncology Based Preclinical CRO and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oncology Based Preclinical CRO.
The global Oncology Based Preclinical CRO market size is projected to grow from US$ 372 million in 2022 to US$ 867.9 million in 2029; it is expected to grow at a CAGR of 12.9% from 2023 to 2029.
The industry's leading producers are Crown Bioscience, Charles River and ICON, with revenues of 18.32 percent, 13.86 percent and 9.13 percent in 2019.
This report presents a comprehensive overview, market shares, and growth opportunities of Oncology Based Preclinical CRO market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Blood Cancer
Solid Tumors
Others
Segmentation by application
In Vitro
In Vivo
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Crown Bioscience
Charles River
ICON
Eurofins Scientific
Taconic Biosciences
Covance
EVOTEC
The Jackson Laboratory
MI Bioresearch
Champion Oncology
Wuxi AppTec.
Xentech
Living Tumor Laboratory

Please note: The report will take approximately 2 business days to prepare and deliver.